glumetinib + osimertinib

Glumetinib combined with osimertinib is an investigational combination therapy primarily studied for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with specific genetic alterations. Glumetinib is a highly selective, orally bioavailable small molecule inhibitor of the c-Met receptor tyrosine kinase (hepatocyte growth factor receptor), which plays a key role in tumor cell proliferation, survival, invasion, metastasis, and angiogenesis. Osimertinib is an oral third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that irreversibly inhibits both EGFR sensitizing mutations and the T790M resistance mutation. The combination aims to overcome resistance mechanisms in EGFR-mutant NSCLC patients who develop MET amplification as a common pathway of acquired resistance to osimertinib monotherapy. Clinical trials have shown that combining glumetinib with osimertinib can be effective and safe as first-line treatment or after progression on prior therapies by targeting both EGFR and MET pathways simultaneously. Developers are investigating this combination in phase 3 clinical trials comparing it against platinum-based chemotherapy for efficacy and safety in NSCLC patients harboring these mutations.

Brand names

HaiyitanTagrisso